eLetters

127 e-Letters

published between 2004 and 2007

  • A need for greater reporting of socio-economic status and race in clinical trials
    Adewale O. Adebajo

    Dear Editor,

    Lee and Kavanagh [1] report on the need for greater reporting of socio-economic status and race in clinical trials.

    This raises the wider issue of encouraging patients from ethnic minorities to participate in clinical trials in the first place.

    There are several known barriers to the involvement of ethnic minorities in clinical trials. Race often co-locates with low socio- econo...

    Show More
  • Still's disease and anti-TNF alpha therapy: the pediatric experience
    Pierre Quartier

    Dear Editor,

    Fautrel et al [1] recently reported the cases of 20 adults with Still's disease who were treated with TNF alpha blocking agents. Most patients only achieved partial remission and there were only 2 cases of sustained remission of more than one year, which contrasts with the much higher response rates observed in patients with rheumatoid arthritis.

    In this paper, the authors never refer...

    Show More
  • Antinuclear antibodies are common in an infectious environment but do not predict SLE
    Adeseye A. Adeniran

    Dear Editor,

    We read with interest the study by Cainelli et al [1] on the presence of antinuclear antibodies (ANA) in normal healthy individuals from an infectious environment. They point out that the presence of ANA may not be predictive of Systemic Lupus Erythematosus in individuals from tropical regions.

    These observations confirm previous such studies from West Africa. We would point out howev...

    Show More
  • Does Tubach’s Shortened WOMAC Function Scale Overcome the Full Length Version’s Shortcomings?
    Paul W Stratford

    Dear Editor,

    Tubach and colleagues [1] propose an 8-item shortened version of the WOMAC physical function subscale which they consider promising for clinical use and large scale surveys and clinical trials.

    The authors report that the shortened measure’s test retest reliability and responsiveness are similar to those of the complete physical function subscale; the internal consistency of the shortened...

    Show More
  • NSAIDs, including coxibs, probably do more harm than good, and paracetamol is ineffective for hip OA
    Jan M. Bjordal

    Dear Editor,

    New EULAR treatment guidelines in hip osteoarthritis were recently reviewed [1]. The recommendations are allegedly based on top level scientific (grade 1a) data, and advocate the use of paracetamol (US: acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase 2 inhibitors (coxibs), in osteoarthritis of the hip. We interpret the underlying data differently...

    Show More
  • Therapeutic potential of statins in rheumatic diseases
    Przemyslaw J. Kotyla

    Dear Editor,

    We read with a great interest article by McInnes and colleagues [1] concerning the beneficial properties of statins in patients with rheumatoid arthritis.

    HMG-CoA reductase inhibitors are widely used compounds introduced primarily as effective cholesterol lowering agents. With time, it has been recognised that effects of statins go far beyond only lipid lowering properties and nowadays they a...

    Show More
  • Should patients with medium risk of disease progression really be avoided in clinical trials?
    Jane S Angwin

    Dear Editor,

    Patient selection can affect required sample sizes and outcomes in randomised clinical trials and the optimal selection may depend on how the tested drug differentially affects patients. Bruynesteyn K et al. [1,2] have investigated these effects in rheumatoid arthritis based on an outcome measure of radiological damage progression.

    An absolute reduction (AR) drug which reduces the expe...

    Show More
  • "In Response to: Autoantibodies and thrombophilia in RA: TNF alpha and TNF alpha blockers-June 2004
    Alan M Mendelsohn

    Dear Editor,

    There has been growing interest in studies evaluating the effects of various disease modifying agents on endothelial dysfunction in patients with rheumatoid arthritis due to the predictive value of such properties on endothelial function on increased or decreased risk of cardiovascular events. We, therefore, read with great interest the article by Doctors Ferraciolo and Gremese in the June 2004 issue...

    Show More
  • Anakinra in the treatment of refractory adult onset Still’s disease
    Pierantonio Ostuni

    Dear Editor,

    We thank Dr Godinho and his co-authors for their report about usefulness of anakinra in the treatment of refractory adult onset Still’s disease (AOSD).

    Not all the patients with AOSD have a similar disease course: 4 different disease patterns (monocyclic systemic, monocyclic chronic articular, polycyclic systemic and polycyclic chronic articular) have been described [1]. On the other hand, c...

    Show More
  • E148Q MEFV sequence variation and familial Mediterranean fever
    Serge Amselem

    Dear Editor,

    We read with great interest the article by Topaloglu et al (Sep. 30 issue) [1] on the implication of the E148Q sequence variation in familial Mediterranean fever (FMF). In our opinion, the best interpretation of this study is not that E148Q is a disease-causing MEFV mutation, but, rather, that this sequence variation is not involved in FMF, or more precisely that the E148Q allele is not impli...

    Show More

Pages